Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496750 · ClinicalTrials.gov registry record · Phase 2
Ketamine for Methamphetamine Use Disorder
A Phase 2 study of Substance Use Disorders and Substance Use, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT06496750 is a Phase 2 study of Substance Use Disorders and Substance Use that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 120 participants, below the 499-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06496750, a Phase 2 study of Substance Use Disorders and Substance Use, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
- DRUG Midazolam Hydrochloride
Study Locations (4)
New Mexico
- Interdisciplinary Substance Use and Brain Injury Facility - Albuquerque
New York
- Addiction Institute of Mount Sinai - New York
South Carolina
- Prisma Health - Greenville
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06496750
The ClinicalTrials.gov registry entry for NCT06496750 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (76% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Ketamine Hydrochloride is the first listed.
NCT06496750 reports 4 study locations spanning 4 distinct geographic areas - top geographies include New Mexico, New York, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06496750 about?
NCT06496750 is a clinical study titled "Ketamine for Methamphetamine Use Disorder". This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, deli...
What is the current status of trial NCT06496750?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-09-11. Estimated completion is 2026-10-15.
What conditions does trial NCT06496750 study?
This clinical trial studies the following conditions: Substance Use Disorders, Substance Use, Methamphetamine Abuse.
What interventions are being tested in trial NCT06496750?
The interventions under investigation include: Ketamine Hydrochloride (DRUG), Midazolam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06496750?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496750 being conducted?
This trial has 4 study locations across New Mexico, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
RAE (Realize, Analyze, Engage)
COMPLETED · Phase 2
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.